Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Rating of “Reduce” from Brokerages

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received an average recommendation of “Reduce” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $14.80.

Several research firms have commented on IART. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wells Fargo & Company decreased their price objective on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, February 27th. Finally, Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth about $25,000. GAMMA Investing LLC increased its stake in Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. raised its position in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. AlphaQuest LLC bought a new position in Integra LifeSciences during the second quarter worth about $73,000. Finally, EMC Capital Management bought a new position in Integra LifeSciences during the second quarter worth about $75,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $9.73 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. Integra LifeSciences has a one year low of $9.36 and a one year high of $24.36. The company has a fifty day moving average price of $11.72 and a 200 day moving average price of $13.06. The stock has a market cap of $758.36 million, a P/E ratio of -1.45 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The business’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the business posted $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.